[
    [
        {
            "time": "",
            "original_text": "万泰生物(603392.SH)副总经理李莎燕减持40万股 减持数量过半 减持股份",
            "features": {
                "keywords": [
                    "万泰生物",
                    "副总经理",
                    "李莎燕",
                    "减持",
                    "40万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "万泰生物：董事、高级管理人员李莎燕减持40万股 减持股份",
            "features": {
                "keywords": [
                    "万泰生物",
                    "董事",
                    "高级管理人员",
                    "李莎燕",
                    "减持",
                    "40万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "万泰生物：公司二价HPV疫苗适用于9-45岁女性，9-14岁只需接种两针，15岁及以上需要接种三针",
            "features": {
                "keywords": [
                    "万泰生物",
                    "二价HPV疫苗",
                    "9-45岁女性",
                    "接种针数"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "万泰生物：公司董监高以集中竞价交易方式减持股份 减持股份",
            "features": {
                "keywords": [
                    "万泰生物",
                    "董监高",
                    "集中竞价交易",
                    "减持股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "万泰生物：九价宫颈癌疫苗二期扩产建设项目完成后，九价HPV疫苗设计产能可增至6000万支/年",
            "features": {
                "keywords": [
                    "万泰生物",
                    "九价宫颈癌疫苗",
                    "二期扩产",
                    "6000万支/年"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]